Figure 1.
Representative immunohistochemistry results of stromal Cav-1 expression in pancreatic tissue.
Paraffin sections were immunostained as described in the methods section. (N) Normal tissue strongly positive for Cav-1 expression; (P) Paracancer tissue moderate for Cav-1 expression; (C) Tumor tissue with negative Cav-1 expression (×400).
Figure 2.
The mRNA expression of stromal Cav-1 in laser-captured samples by RT-PCR and Real-time PCR.
A: Schematic diagram representing the LCM technique. B: mRNA expression of stromal Cav-1 in laser-captured samples as determined by RT-PCR. C: Quantification of mRNA by real-time quantitative PCR. Data from at least three independent experiments with duplicate determinations are expressed as means ± SEM. (N) Normal tissue; (P) Paracancer tissue; (C) Tumor tissue. *P<0.05 was considered statistically significant.
Figure 3.
Immunodetection of Cav-1 protien in CAFs, PAFs, and NFs.
A: Cell morphological characteristic of CAFs, PAFs, and NFs (×100). Extracted CAFs from pancreatic cancer and PAFs and NFs from paracancerous tissue and non-cancerous partial pancreatectomy specimens. B: Different vimentin expression levels in stroma CAFs, PAFs, and NFs were assessed by immunohistochemistry (×200). C: Cav-1 protein expression in CAFs and NFs stained with FITC labeling-IgG antibody and analyzed by confocal microscopy. Cav-1 fluorescence signal in CAF is lower than in PAFs and NFs (×200). (CAFs) Cancer associated fibroblasts; (PAFs) Paracancerous associated fibroblasts; (NFs) Normal associated fibroblasts.
Table 1.
Association between stromal Cav-1 expression and clinicopathologic factors in pancreatic cancers.
Figure 4.
Representative photomicrograph of HER-2/neu gene amplification in pancreatic cancer.
(N) Normal tissue negative for HER-2/neu gene amplification; (P) Paracancer tissue moderate for HER-2/neu gene amplification; (C) Tumor tissue positive for HER-2/neu gene amplification (×1000).
Table 2.
Relationship between expression of stromal Cav-1 and HER-2/neu amplification.
Figure 5.
CTCs stained with anti-CD45-CEP8-DAPI in peripheral blood of pancreatic cancer patients.
A: CTCs negative in patients with stromal Cav-1 loss. B: CTCs positive in patients with stromal Cav-1 loss. C: CTCs negative in patients with stromal Cav-1 expression. D: CTCs positive in patients with stromal Cav-1 expression. The white scale bar indicates 10 µm (x400).
Figure 6.
Kaplan–Meier analysis of the overall postoperative survival curves in pancreatic cancer cases according to immunohistochemical staining as positive or negative of stromal Cav-1 expression.